Amplification or overexpression of EGFR is present in 60% of GBM tumors, with more than 40% of those tumors carrying the EGFR variant III mutant (EGFRvIII), a mutation that results in a truncated receptor that causes constitutive signaling pathway activation [9, 10, 12, 13]. The gene discussed is EGFR; the disease is glioblastoma.